A recent report of a small-molecule Bcl-2 BH4 domain antagonist that may kill lung cancer cells, at least in part, by inhibiting Bcl-2–IP3R interaction suggests the feasibility of such an approach.48 Ultimately, it is hoped that actual therapeutic agents can be developed based on the proof-of-principle evidence and patterned after BIRD-2. The gene discussed is BCL2; the disease is lung cancer.